Loading...
•
Mar 31, 2023
Cardiff Oncology Q1 2023 Earnings Report
Cardiff Oncology reported first-quarter 2023 results and provided a business update.
Key Takeaways
Cardiff Oncology reported its first-quarter 2023 results, highlighting the dosing of the first patient in the Phase 2 ONSEMBLE trial and the appointment of Fairooz Kabbinavar as Chief Medical Officer. The company's cash, cash equivalents, and short-term investments totaled approximately $97 million as of March 31, 2023, which is projected to fund operations into 2025.
First patient dosed in ONSEMBLE Phase 2 randomized trial of Onvansertib in patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC).
Fairooz Kabbinavar, MD, FACP, appointed as Chief Medical Officer.
Full membership of Scientific Advisory Board (SAB) introduced.
Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025.
Forward Guidance
Cardiff Oncology anticipates several data readouts in the coming quarters, including mPDAC and SCLC data in mid-2023, TNBC data in late 2023 or early 2024, and mCRC randomized data in the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...